Physician profile
Alan E Orellana
NPI 1760692248
$4,823.96
in general payments reported to CMS, 2019-2025
25 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $662 · 2021: $495 · 2022: $464 · 2023: $969 · 2024: $796 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,383.89 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $618.23 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.08 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $474.79 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $398.63 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Abiomed | $391.71 | 2023-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $132.50 | 2021-2025 | Dupixent |
| Genzyme Corporation | $129.12 | 2022-2025 | |
| Amgen INC. | $123.15 | 2019 | |
| Grifols USA, LLC | $106.96 | 2019-2024 | Prolastin-C Liquid |
| Abbvie INC. | $75.70 | 2021-2023 | |
| Circassia INC. | $49.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.99 | 2022 | |
| Viatris Specialty LLC | $40.55 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $37.14 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.01 | 2024-2025 | Winrevair |
| Philips North America LLC | $30.04 | 2019-2024 | (Ak6) Vest Therapy |
| Allergan, INC. | $29.04 | 2020 | |
| Insmed, INC. | $28.44 | 2021-2025 | Arikayce |
| Genentech USA, INC. | $26.19 | 2019 | |
| United Therapeutics Corporation | $24.51 | 2019 | |
| Nabriva Therapeutics, Plc | $21.55 | 2020 | |
| Shire North American Group INC | $15.64 | 2019 | |
| Chiesi USA, INC. | $12.09 | 2019 | |
| Inogen, INC. | $4.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Orellana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.